Peptides · Peptide comparison
Imunofan vs Thymosin Alpha-1
Synthetic hexapeptide derived from thymopoietin with immunomodulatory, antioxidant, and hepatoprotective properties
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Immune
Healing & Recovery
Anti-Aging
Immune Activation
Infection Fighting
Immune Balance
Technical data
Compound specifications
Imunofan
- Molecular formula
- C36H61N13O10
- Molecular weight
- 836.0 g/mol
- Half-life
- Approximately 2-4 hours (intranasal administration)
- Bioavailability
- ~90-95% (subcutaneous injection)
- CAS number
- Not assigned (Russian pharmacopeia compound)
Thymosin Alpha-1
- Molecular formula
- C129H215N33O55
- Molecular weight
- 3108.32 g/mol
- Half-life
- Approximately 2 hours
- Bioavailability
- High when injected subcutaneously (rapid absorption, peak at ~2 hours)
- CAS number
- 62304-98-7
Protocols
Dosing compared
Imunofan
Subcutaneous
- 45 mcg per doseOnce daily or every other day · Course of 5-15 injections (about 10-30 days)Standard injectable dose per the Russian pharmacopeia product label; the single subcutaneous dose is 45 mcg with a maximum daily dose of 45 mcg. Given in courses depending on the indication [1][5].
Intramuscular
- 45 mcg per doseOnce daily or every other day · Course of 5-15 injections (about 10-30 days)Same 45 mcg single dose can be given intramuscularly; identical course structure to the subcutaneous route [1][5].
Intranasal
- 50 mcg per dose (one spray in each nostril)Once to twice daily · 8-15 days per courseIntranasal spray delivers 50 mcg per dose; one dose into each nasal passage once daily for 8-10 days, or twice daily for 10-15 days for certain indications [5].
Thymosin Alpha-1
Subcutaneous injection
- 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
- 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].
Applications
Best suited for
Imunofan
- Cancer Adjuvant Therapy
- Imunofan enhances the body's reserve capacity to inactivate free radicals and oxidants during chemotherapy and radiation, substantially reducing toxic reactions and enabling continuity of cancer treatment. [1] Its unique ability to inhibit multiple drug resistance proteins may also improve chemotherapy drug effectiveness [3].
- Chronic Viral Hepatitis
- With established hepatoprotective properties and immune-restoring capabilities, Imunofan is used as adjunctive therapy in chronic hepatitis B and C, helping restore antiviral immunity and supporting liver function recovery [1].
- Chronic Infections with Immunodepression
- Patients with chronic infections (brucellosis, opportunistic infections in HIV) who display cell-mediated immunodepression may benefit from Imunofan's three-phase immune restoration, particularly the sustained slow-phase effect lasting up to 4 months [1][6].
- Oxidative Stress Reduction
- The rapid antioxidant phase makes Imunofan valuable for conditions involving elevated oxidative stress, as it directly inactivates free radicals and peroxide compounds while restoring the body's oxidative-antioxidant balance [1].
Thymosin Alpha-1
- Chronic Hepatitis B or C Support
- Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
- Cancer Treatment Support
- When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
- Age-Related Immune Decline
- As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
- Severe Infection Recovery
- In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety profile
Side effects
Imunofan
Common
- Injection site reaction
- Transient headache
- Nasal irritation (intranasal form)
- Transient mild fever
- Mild fatigue
- Gastrointestinal discomfort (suppository form)
Uncommon
- Allergic reaction
Serious
- Anaphylactic reaction / Severe hypersensitivity
Thymosin Alpha-1
Common
- Injection site reactions
Uncommon
- Mild fatigue
- Flu-like symptoms
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research status
Safety & evidence
Imunofan
- Evidence level
- Limited human trials
- FDA status
- Research compound
- Safety overview
- Imunofan (Iletin-alpha, a synthetic tetrapeptide) demonstrates good tolerability in Russian clinical practice spanning 20+ years [7] with oral and parenteral administration. Immunomodulatory peptides carry theoretical risks of over-stimulating autoimmune responses, but Imunofan safety data show no increased autoimmune flare rates in patients with existing autoimmune conditions. Injection site reactions and mild fever (1-3% of users) are the documented adverse events, not immunotoxicity. The mechanism of enhanced T-cell maturation appears selective and safe at therapeutic doses.
Contraindications
- Known hypersensitivity to imunofan or excipients
- Pregnancy complicated by Rh-conflict (contraindicated)
- Children under 2 years of age
- Severe allergic conditions in acute exacerbation
Thymosin Alpha-1
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
- Safety overview
- Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- Organ transplant recipients on immunosuppressants
- Active autoimmune disease flares
- Known allergy to thymosin peptides
- Pregnancy or breastfeeding
- Children under 18 without medical supervision
Decision guide
Which is right for you?
Imunofan
Choose Imunofan if…
- Immune system restoration and modulation
- Adjunctive therapy during chemotherapy and radiation
- Support during chronic hepatitis treatment
- Reducing oxidative stress and free radical damage
Thymosin Alpha-1
Choose Thymosin Alpha-1 if…
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support